Troglitazone was used as an oral antidiabetic drug for treating type 2 diabetes mellitus by improving insulin sensitivity. It belongs to the thiazolidinedione (TZD) class and worked as a PPAR-γ agonist to regulate glucose and lipid metabolism. It also showed potential anti-inflammatory and antioxidant effects due to its vitamin E–like structure. It is grouped under the following drug class(es): Hypoglycemics and Thiazolidinediones. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Rezulin, Romglizone, Noscal, Prelay and Romozin. Its PubChem CID is 5591.
Troglitazone
| CAS No | 97322‑87‑7 |
|---|---|
| Molecular Formula | C24H27NO5S |
| Molecular Weight | 441.5 g/mol |
| Synonyms | 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Troglitazone was used as an oral antidiabetic drug for treating type 2 diabetes mellitus by improving insulin sensitivity. It belongs to the thiazolidinedione (TZD) class and worked as a PPAR-γ agonist to regulate glucose and lipid metabolism.
The listed CAS number is 97322‑87‑7.
The listed molecular formula is C24H27NO5S.
The listed molecular weight is 441.5 g/mol.
5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione.
The source lists Rezulin, Romglizone, Noscal, Prelay and Romozin.